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A 63-year-old woman who had never smoked, was 
diagnosed to have a stage IV (T2bN3M1a) right upper lobe 
lung adenocarcinoma with metastasis to the right hilar, 
subcarinal, right paratracheal and right supraclavicular 
lymph nodes in addition to contralateral lung nodules on 
computed tomography (CT) scan in July 2016 (Figure 1A). 
Excision biopsy of the right supraclavicular lymph node 
revealed metastatic adenocarcinoma with epidermal 
growth factor receptor (EGFR )  exon 19 delet ion 
mutation detected by Therascreen® EGFR RGQ PCR 
Kit (Qiagen, Manchester Ltd., UK). Despite an initial 
radiological response on CT scan one month after starting 
gefitinib 250 mg once daily, CT examination another 
2 months later showed progression of disease (PD) 
(Figure 1B). Treatment was switched to afatinib 40 mg once 
daily in December 2016. After switching to afatinib, CT 
scan examination 1 and 3 months later, respectively showed 
partial response (Figure 1C). Afatinib dose was reduced to 
30 mg once daily in March 2017 because of grade 2 diarrhea 
and drug-induced hepatitis. CT scan in June 2017 showed 
PD (Figure 1D). EGFR exon 19 deletion and exon 20 
T790M mutations were not detected in circulating tumor 
DNA by droplet digital PCR (Sanomics, Hong Kong). In 
comparison to the metastatic adenocarcinoma found on 
initial excision biopsy of the right supraclavicular lymph 
node (Figure 2), needle biopsy of the rapidly enlarging right 
upper lobe tumor in early July 2017 showed a biphasic 
pattern of epithelial and sarcomatous differentiation (Figure 
3A,B,C,D). The epithelial cells were immunoreactive to 
pancytokeratin and TTF-1 while the sarcomatous elements 
were immunoreactive to vimentin. Molecular studies on the 
lung biopsy specimen were negative for EGFR mutation 
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(both exon 19 deletion and T790 mutation), anaplastic 
lymphoma kinase (ALK) rearrangement and HER2 
mutation.  
She succumbed to rapid PD in August 2017 before the 
initiation of systemic chemotherapy. 
Discussion 
To our knowledge, this is the first reported case of EMT 
causing acquired resistance to the second-generation EGFR-
TKI, afatinib in a patient with advanced NSCLC harboring 
a sensitizing EGFR mutation. EMT has by far only been 
reported as a likely mechanism of acquired resistance in 
afatinib-resistant cell lines but not in patients (1). 
In EMT, epithelial cells transform to mesenchymal stem 
cells by losing their cell polarity and cell-to-cell adhesion, 
gaining invasive and migratory properties, accompanied 
by upregulation of anti-apoptotic signals and changes in 
the expression of molecular marker proteins, i.e., down-
regulation of E-cadherin and up-regulation of vimentin, 
fibronectin, and N-cadherin (2). Expression of mesenchymal 
markers correlates with a poor prognosis and an inferior 
response to EGFR-TKIs in non-small cell lung cancer 
(NSCLC) (2). The sarcomatous elements in this patient 
were immunoreactive to vimentin, a canonical marker 
consistent with EMT despite N-cadherin and fibronectin 
not performed. 
Acquired resistance due to EMT has rarely been reported 
in patients treated with gefitinib and erlotinib (3). In 37 
EGFR-mutated patients treated with erlotinib or gefitinib, 
EMT was detected in only three patients on rebiopsies at 
disease progression (3). Interestingly, EMT has not been 
described as a resistance mechanism to afatinib in NSCLC 
patients (4). EMT which may co-exist with other resistance 
Figure 1 Serial computed tomography images. (A) Right upper lobe tumor measuring 5.6 cm × 4.4 cm × 4.1 cm, enlarged right paratracheal 
lymph nodes and bilateral lung nodules in July 2016; (B) enlargement of primary tumor and mediastinal lymph nodes showing PD 3 months 
after initiation of gefitinib therapy; (C) partial response with smaller primary tumor and mediastinal lymph nodes 3 months after switching to 
afatinib; (D) larger primary tumor with new pericardial invasion and increasing lung nodules in June 2017. PD, progression of disease.
Figure 2 Hematoxylin and eosin staining of initial supraclavicular 
lymph node biopsy showing moderately  di f ferentiated 
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mechanisms causing EGFR-TKI treatment failure may be 
underdiagnosed due to the infrequent performance of tissue 
rebiopsies and overreliance on liquid biopsies. 
There is a high possibility however that there was 
much tumor heterogeneity in the original lung tumor, as 
evidenced by a relatively short response period to first-
generation TKI (2 months with gefitinib) and second-
generation TKI (6 months with afatinib) in comparison to 
the reported time-to-treatment failure of 13.7 months with 
afatinib and 11.5 months with gefitinib (5). 
In line with tumor heterogeneity, it would be almost 
impossible to ascertain if this case represented a case of pure 
acquired resistance to afatinib due to EMT as an acquired 
resistance mechanism, or the emergence of a distinct 
subclone of tumor cell population which was resistant 
to afatinib and exhibiting EMT after initial response to 
afatinib by the original subclone of tumors with EGFR exon 
19 deletion. The tumor was not tested for other reported 
afatinib-acquired resistance mechanisms such as MET gene 
amplification, KRAS gene amplification, and EGFR C797S, 
L792F and V843I mutations.
Interestingly, upon PD to afatinib, both circulating 
tumour DNA (ctDNA) and lung biopsy were negative for 
the original EGFR mutation. Concordance rates between 
ctDNA and tumor tissues for common EGFR mutations 
in the literature have a wide variation ranging from 27.5% 
to 100% (6) with pooled sensitivities from two meta-
analyses reported to be 67.4% and 62%, and specificities 
of 93.5% and 95.9%, respectively (7,8). Despite epithelial 
cells being present in the lung specimen, these cells do 
not exhibit the original EGFR mutation, thus suggesting 
that these cells have developed acquired resistance, 
possibly through the loss of the mutant EGFR gene allele 
which has been reported in cell lines resistant to first-
generation TKIs (9). 
Therapeutic strategies to reverse EMT in patients 
with acquired resistance to EGFR-TKI include blocking 
M2 muscarinic receptor signalling (10), targeting EMT 
with histone deacetylase inhibitors such as entinostat (11) 
and MEK-inhibitors such as selumetinib (2), inhibition 
of microRNAs (12), immunotherapy (13); and inhibiting 
fibroblast growth factor receptor-1 (14).
Figure 3 Hematoxylin and eosin staining of needle biopsy of enlarging right upper lobe tumor shows epithelial elements (arrow) juxtaposed 
with sarcomatous stroma [S] (A); epithelial elements (arrows) are stained positive for pancytokeratin (MNF116) (B) and TTF-1 (C) 
but negative for vimentin (D) (immunohistochemical staining). The sarcomatous stroma [S] is only immunoreactive for vimentin (D). 
Magnification: (A) ×10; (B-D) ×20.
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Conclusions
This is the first report of EMT causing acquired resistance 
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